BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

INDICATION: Spinal muscular atrophy (SMA) Cell culture and mouse studies suggest inhibiting SQSTM1 could help treat SMA, which is caused by SMN1 mutations. In motor neuron cells derived from a mouse model of SMA or...
BioCentury | Aug 11, 2017
Clinical News

Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and neck cancer. Patients receive...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 21, 2017
Clinical News

Rocapuldencel-T: Additional Ph III ADAPT data

...loss of $52.3 million. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd. (SGX:300006...
BioCentury | Feb 24, 2017
Clinical News

Rocapuldencel-T: Ph III ADAPT data

...June 20, 2016 ). Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd. (SGX:300006...
BioCentury | Feb 3, 2017
Clinical News

Hypericin regulatory update

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to SGX301 to treat cutaneous T cell lymphoma (CTCL). SGX301 is a topical phototherapeutic agent that inhibits heat shock protein...
BioCentury | Dec 14, 2016
Clinical News

Dusquetide regulatory update

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to dusquetide from Soligenix to treat severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy. Dusquetide is...
Items per page:
1 - 10 of 227
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
BioCentury | May 1, 2018
Distillery Therapeutics

Neurology

INDICATION: Spinal muscular atrophy (SMA) Cell culture and mouse studies suggest inhibiting SQSTM1 could help treat SMA, which is caused by SMN1 mutations. In motor neuron cells derived from a mouse model of SMA or...
BioCentury | Aug 11, 2017
Clinical News

Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and neck cancer. Patients receive...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 21, 2017
Clinical News

Rocapuldencel-T: Additional Ph III ADAPT data

...loss of $52.3 million. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd. (SGX:300006...
BioCentury | Feb 24, 2017
Clinical News

Rocapuldencel-T: Ph III ADAPT data

...June 20, 2016 ). Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Chongqing Lummy Pharmaceutical Co. Ltd. (SGX:300006...
BioCentury | Feb 3, 2017
Clinical News

Hypericin regulatory update

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to SGX301 to treat cutaneous T cell lymphoma (CTCL). SGX301 is a topical phototherapeutic agent that inhibits heat shock protein...
BioCentury | Dec 14, 2016
Clinical News

Dusquetide regulatory update

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) granted promising innovative medicine (PIM) designation to dusquetide from Soligenix to treat severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy. Dusquetide is...
Items per page:
1 - 10 of 227